semaglutide lean mass loss and muscle loss: Hidden risk for plans and PBMs Once-weekly semaglutide 2.4 mg led

When Should You Be Concerned

Who Should Not Consider GLP-1 Therapy Without Specialist Oversight Regardless of which telehealth platform you are evaluating, GLP-1 medications carry specific contraindications that require medical attention before proceeding

NICE guidance on obesity management (CG189 and recent technology appraisals) recommends a stepwise approach: First-line: Lifestyle interventions including dietary modification, increased physical activity, and behavioural support Pharmacotherapy: Consider when BMI 35 kg/m (or 30 kg/m with comorbidities) and lifestyle measures have been insufficient Licensed options: Orlistat remains a primary pharmacological option in NHS formularies, with GLP-1 receptor agonists like semaglutide (Wegovy) now available through specialist services for those with BMI 35 kg/m (or 30 kg/m with comorbidities) and at least one weight-related comorbidity Bariatric surgery: Considered for those with BMI 40 kg/m (or 35 kg/m with comorbidities) when other measures have failed NICE guidance emphasises using licensed medications with established safety profiles and does not recommend combining weight loss drugs without robust evidence

As a result, semaglutide users lose around 14-17 percent of their body weight on average within four years